Immunome (IMNM) Receivables (2021 - 2022)

Immunome (IMNM) posted Receivables of $18.2 million for Q2 2022, up 9000.0% on a QoQ basis from $200000.0 in Q1 2022.

Immunome (IMNM) Receivables (2021 - 2022) Analysis & Trends

Immunome's Receivables history runs 2 years deep, the most recent figure standing at $18.2 million for Q2 2022.

Quarterly Receivables changed N/A year-over-year to $18.2 million in Q2 2022, while the trailing twelve-month figure through Jun 2022 was $18.2 million (changed N/A YoY) and the FY2021 annual result came in at $200000.0, changed N/A from the prior year.
Receivables was $18.2 million for Q2 2022 at Immunome, up from $200000.0 in the prior quarter.
Across five years, Receivables topped out at $18.2 million in Q2 2022 and bottomed at $200000.0 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	4.97 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	938.02 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	1.13 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	2.00 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	5.73 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	1.93 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Immunome	2.49 Bn	1.91 Bn	-	-

Download Data